Menus Subscribe Search

Class of Antipsychotics Ineffective in PTSD Treatment

• August 10, 2011 • 4:00 AM

The future may hold a drug therapy for treating post-traumatic stress disorder, but some of the popular choices of the last few years, like Risperdal, won’t be part of it.

A new era of psychopharmacology combined with two wars in Asia has created its own surge in treating combat stress with prescription drugs. For tough cases doctors have even prescribed antipsychotics. But all drugs are not created equal, and a new study claims that one class of antipsychotic is no better than a placebo for treating post-traumatic stress.

The study underlines that there is no drug for PTSD symptoms. The researchers concentrated on one medication, Risperdal, but the results may apply to a whole class of antipsychotics that work on neurotransmission in the brain.

“It definitely calls into question the use of anti-psychotics in general for PTSD,” Charles Hoge, a senior scientist at the Walter Reed Army Institute of Research, told The New York Times.

Antipsychotics like Risperdal target the way brain cells handle neurotransmitters like serotonin and dopamine. In that sense they’re similar to antidepressants. They ease a symptom that might correspond to PTSD, but recent research indicates that combat stress can cause physical damage to the brain. The cells themselves may have changed shape or started to work in a different way.

Basically, antipsychotics may affect the brain on too shallow a level to help. But there might be hope for drugs that try to fix cells on a level closer to a person’s genes.

“We don’t understand the disorder well enough. All we have are puzzle pieces,” says Dr. Ulrike Schmidt, a PTSD expert at the Max Planck Institute for Psychiatry in Munich. “But I can imagine that with more high-throughput experiments we will identify target genes, or the proteins they produce, which we can then try to steer with pharmaceuticals.”

Her opinion is that the right genes or proteins might be found roughly “in the household of stress hormones,” like cortisol.

Schmidt’s research has shown that PTSD causes semi-permanent damage not only to parts of the brain, but also to the epigenome, the complex of molecules that surrounds a person’s DNA and influences which genes are expressed. It’s like a blow to a person’s firmware — damage to a system that tells the body what to do. It’s not irreversible, though a predisposition for it could be passed on to another generation.

Antipsychotics — widely prescribed as they are — may seem off the mark because psychosis itself is not a typical outcome of post-traumatic stress (the way depression is). But symptoms of psychosis and PTSD can overlap. And doctors have been prescribing antipsychotics “based almost entirely on their experience with them and how they expect them to work,” according to the Times. [class name="dont_print_this"]

European Dispatch

EUROPEAN DISPATCH
Michael Scott Moore complements his standing feature in Miller-McCune magazine with frequent posts on the policy challenges and solutions popping up on the other side of the pond.

[/class]

The big caveat is that PTSD isn’t well understood. And some vets may have been prone to certain psychoses to start with. The current study didn’t select for them.

This research into molecules and brain behavior may wind up emphasizing that PTSD is too fine-grained and changeable to be treated entirely with drugs. As a disorder it seems to straddle the mysterious boundary between the mind and the brain. The simplest treatment — for most people — may still be sports, like surfing or biking, combined with talk therapy.

Schmidt helps run a clinic in Munich for people with severe post-traumatic stress, where the treatment involves drugs as well as therapy. “We have psychotherapy that includes depth psychology, gestalt therapy and behavioral-therapy elements. We never say, ‘Only behavioral therapy is good’ — we combine them. And we try to ease certain symptoms with medication. For example, a patient with severe sleeping problems might receive medication for that. … But the big goal is to lighten the therapy, or speed it up, with a PTSD-specific medication.”

One other non-pharmacological treatment, of course, would be to fight fewer wars.

Sign up for the free Miller-McCune.com e-newsletter.

“Like” Miller-McCune on Facebook.

Follow Miller-McCune on Twitter.

Add Miller-McCune.com news to your site.

Subscribe to Miller-McCune

Michael Scott Moore
Michael Scott Moore was a 2006-2007 Fulbright fellow for journalism in Germany, and The Economist named his surf travelogue, "Sweetness and Blood," a book of the year in 2010. His first novel, "Too Much of Nothing," was published by Carroll & Graf in 2003, and he’s written about politics and travel for The Atlantic Monthly, Slate, the Los Angeles Times, and Spiegel Online in Berlin, where he serves as editor-at-large.

More From Michael Scott Moore

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

July 31 • 4:00 PM

Thank You for Your Service: How One Company Sues Soldiers Worldwide

With stores near military bases across the country, the retailer USA Discounters offers easy credit to service members. But when those loans go bad, the company uses the local courts near its Virginia headquarters to file suits by the thousands.


July 31 • 2:00 PM

A New York State of Fracking

Court cases. A governor’s moratorium. Pending health study. A quick guide to the state of fracking in New York.


July 31 • 11:17 AM

How California Could Power Itself Using Nothing but Renewables

We don’t need fossil fuels.


July 31 • 8:00 AM

Should Athletes Train Their Memories?

Sure, but it probably won’t help.


July 31 • 6:00 AM

Universal Basic Income: Something We Can All Agree on?

According to Almaz Zelleke, it’s not a crazy thought.


July 31 • 4:00 AM

Medical Dramas Produce Misinformed, Fatalistic Viewers

New research suggests TV doctor dramas leave viewers with skewed impressions of important health-related topics.


July 30 • 4:00 PM

Still the World’s Top Military Spender

Although declining in real terms, the United States’ military budget remains substantial and a huge drain on our public resources.



July 30 • 2:04 PM

The Rise of the Nuisance Flood

Minor floods are afflicting parts of Maryland nearly 10 times more often than was the case in the 1960s.


July 30 • 2:00 PM

The (Mostly Awful) Things You Learn After Investigating Unpaid Internships for a Year

Though the intern economy remains opaque, dialogue about the role of interns in the labor force—and protections they deserve—is beginning to take shape.


July 30 • 12:00 PM

Why Coffee Shortages Won’t Change the Price of Your Frappuccino

You’re so loyal to Starbucks—and the company knows it—that your daily serving of caffeine is already marked up beyond the reach of any fluctuations in supply.



July 30 • 10:00 AM

Having Difficult Conversations With Your Children

Why it’s necessary, and how to do it.


July 30 • 8:00 AM

How to Make a Convincing Sci-Fi Movie on a Tight Budget

Coherence is a good movie, and its initial shoot cost about the same amount of money as a used Prius.


July 30 • 6:00 AM

Are You Really as Happy as You Say You Are?

Researchers find a universal positivity bias in the way we talk, tweet, and write.


July 30 • 4:00 AM

The Declining Wage Gap for Gay Men

New research finds gay men in America are rapidly catching up with straight married men in terms of wages.


July 30 • 2:00 AM

LeBron James Migration: Big Chef Seeking Small Pond

The King’s return to Cleveland is a symbol for the dramatic shift in domestic as well as international migration.


July 29 • 4:00 PM

Are Children Seeking Refuge Turning More Americans Against Undocumented Immigrants?

A look at Pew Research Center survey data collected in February and July of this year.


July 29 • 2:00 PM

Under Water: The EPA’s Ongoing Struggle to Combat Pollution

Frustration and inaction color efforts to enforce the Clean Water Act.


July 29 • 12:40 PM

America’s Streams Are Awash With Pesticides Banned in Europe

You may have never heard of clothianidin, but it’s probably in your local river.


July 29 • 12:00 PM

Mining Your Genetic Data for Profit: The Dark Side of Biobanking

One woman’s personal story raises deep questions about the stark limits of current controls in a nascent industry at the very edge of the frontier of humans and technology.


July 29 • 11:23 AM

Where Should You Go to College?


July 29 • 10:29 AM

How Textbooks Have Changed the Face of War

War is more personal, less glorious, and more hellish in modern textbooks than in the past. But there’s still room for improvement.


July 29 • 10:00 AM

The Monolingual American: Why Are Those Outside of the U.S. Encouraging It?

If you are an American trying to learn German in a large German town or city, you will mostly hear English in return, even when you give sprechen your best shot.


July 29 • 8:00 AM

The Elusive Link Between Casinos and Crime

With a study of the impact of Philadelphia’s SugarHouse Casino, a heated debate gets fresh ammunition.


Follow us


Subscribe Now

The Rise of the Nuisance Flood

Minor floods are afflicting parts of Maryland nearly 10 times more often than was the case in the 1960s.

America’s Streams Are Awash With Pesticides Banned in Europe

You may have never heard of clothianidin, but it's probably in your local river.

How Textbooks Have Changed the Face of War

War is more personal, less glorious, and more hellish in modern textbooks than in the past. But there’s still room for improvement.

NASA Could Build Entire Spacecrafts in Space Using 3-D Printers

This year NASA will experiment with 3-D printing small objects in space. That could mark the beginning of a gravity-free manufacturing revolution.

The Big One

One in two full-time American fast-food workers' families are enrolled in public assistance programs, at a cost of $7 billion per year. July/August 2014

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.